Immune-related eight-lncRNA signature for improving prognosis prediction of lung adenocarcinoma

J Clin Lab Anal. 2021 Sep 22;e24018. doi: 10.1002/jcla.24018. Online ahead of print.


Background: Lung adenocarcinoma (LUAD) is the leading cause of cancer-related deaths worldwide. Therefore, the identification of a novel prediction signature for predicting the prognosis risk and survival outcomes is urgently demanded.

Methods: We integrated a machine-learning frame by combing the Cox regression and Least Absolute Shrinkage and Selection Operator (LASSO) regression model to identify the LUAD-related long non-coding RNA (lncRNA) survival biomarkers. Subsequently, the Spearman correlation test was employed to interrogate the relationships between lncRNA signature and tumor immunity and constructed the competing endogenous RNA (ceRNA) network.

Results: Herein, we identified an eight-lncRNA signature (PR-lncRNA signature, NPSR1-AS1, SATB2-AS1, LINC01090, FGF12-AS2, AC005256.1, MAFA-AS1, BFSP2-AS1, and CPC5-AS1), which contributes to predicting LUAD patient's prognosis risk and survival outcomes. The PR-lncRNA signature has also been confirmed as the robust signature in independent datasets. Further parsing of the LUAD tumor immune infiltration showed the PR-lncRNAs were closely associated with the abundance of multiple immune cells infiltration and the expression of MHC molecules. Furthermore, by constructing the PR-lncRNA-related ceRNA network, we interrogated more potential anti-cancer therapy targets.

Conclusion: lncRNAs, as emerging cancer biomarkers, play an important role in a variety of cancer processes. Identification of PR-lncRNA signatures allows us to better predict patient's survival outcomes and disease risk. Finally, the PR-lncRNA signatures could help us to develop novel LUAD anti-cancer therapeutic strategies.

Keywords: long non-coding RNA; lung adenocarcinoma; machine learning; prognosis; tumor immunoactivity.